Orient EuroPharma Co., Ltd. a specialty pharmaceutical company focused in marketing and commercialization with subsidiaries across Hong Kong, Malaysia, Singapore, Philippines with a strong sales network of 360 dedicated and experienced sales representatives and Debiopharm Group™ announced the signature of a distribution agreement for the commercialization and promotion of Pamorelin® in South East Asia.
Under the terms of the agreement, Orient EuroPharma acquires exclusive marketing and sales rights for Pamorelin® in Singapore, its first launch territory. The product is exported in finished bulk from Debiopharm Research and Manufacturing SA to Orient EuroPharma. Pamorelin® will be made available primarily to urologists and oncologists across Singapore.